Article

Diabetes mellitus aid helps decision making

Use of the Diabetes Medication Choice cards can help patients with diabetes mellitus (DM) and their primary care physicians by increasing patients’ involvement in making decisions about DM medications.

Use of the Diabetes Medication Choice cards can help patients with diabetes mellitus (DM) and their primary care physicians by increasing patients’ involvement in making decisions about DM medications. However, adherence to treatment and outcomes may not be improved.

Mullan and coworkers developed the decision aid, a patient-friendly tool that describes 5 antihyperglycemic medications, their treatment burden, and their effect on hemoglobin A1c (HbA1c) levels. The aid was used by 21 randomly selected physicians; the results were compared with those achieved by 19 doctors who administered usual care and distributed an educational pamphlet. Adherence to treatment was monitored via telephone at 1, 3, and 6 months and pharmacy record review at 6 months after the physician visit.

Patients introduced to the decision aid found it helpful. They became more knowledgeable about antihyperglycemic medications than the usual-care patients and more engaged in deciding about their care. Adherence to medications at 6 months was good in both groups but better in the usual-care group. The decision aid also did not affect glycemic control, as assessed by HbA1c levels, or patient-reported health status.

The authors noted that their findings, although preliminary, may begin to inform policy about patient involvement in health care decisions.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.